Recursion Pharmaceuticals Inc. $(RXRX)$ has announced the acquisition of Rallybio's full interest in their joint ENPP1 inhibitor program, REV102, designed for the treatment of hypophosphatasia $(HPP)$, a rare genetic disorder. The acquisition includes an associated backup molecule. This move grants Recursion full ownership of the program, allowing the company to expedite the development of what could become the first oral disease-modifying therapy for HPP. Currently in IND-enabling studies, REV102 is expected to enter Phase 1 clinical trials in the second half of 2026. The program aims to address the underlying cause of HPP by inhibiting the enzyme ENPP1, potentially improving bone mineralization. Results of these studies have yet to be presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。